Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70% so far this year. Exelixis is, …
The stock is trading 48.31% above its 200-day moving average. Moreover, shares of ImmunoGen, which develops …
The stock rose 1.03% or $0.45 reaching $44.23. About 16,807 shares traded. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since August 15, 2016 and is uptrending. It has outperformed by 9.10% the S&P500. Harel Insurance …
Unfortunately, Incyte posted a loss on the year despite making an incredibly recovery from its February lows. Looking ahead, one analyst sees solid upside for this stock. Credit Suisse has an Outperform rating with a $137 price target, …
Eric H. Siegel, EVP disclosed the sale of 1,820 shares of (INCY). The shares were purchased at an average price of $130.00. Siegel now owns $2,200,120 of the stock per the Form 4 SEC filing. Eric H. Siegel, EVP reported the sale of …
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the …
Incyte, a $25 billion biotech company, revealed some new data about its cancer drugs on Wednesday, and the stock popped. The drugmaker, which has one approved product to treat bone-marrow disorders, is developing a cancer …
Boston, MA 10/04/2013 (wallstreetpr) – Incyte Corporation (NASDAQ:INCY) has announced the results of a 28-day, PhaseII, placebo-controlled clinical-trial that was conducted on 50 patients suffering from chronic plaque psoriasis, for …
Incyte stock price ended the last trading day at 128.7. Stock price or share price can be used to find the total market value of a company. Incyte market cap stands at 25.91B as of 04 Aug, 2017. Incyte valuation can be different from its …